Cancer Treatment in Patients With — Past or Active Tuberculosis

In most situations, active TB needs to be under treatment before or alongside chemotherapy, because chemotherapy suppresses the immune system in ways that allow TB to spread rapidly through the body. How long you need to be on TB treatment first depends on how urgently the cancer needs treating and how well the TB is responding. This is a decision your oncologist and TB specialist make together — there is no single answer that applies to everyone, and it is not something either team should decide alone.

Not directly. TB medicines continue to act on the bacteria regardless of cancer treatment. However, chemotherapy suppresses the immune system that helps your body clear the infection, which can slow the overall response to TB treatment. Your team will monitor TB response through sputum tests or other assessments during cancer treatment. The two programmes run in parallel — neither pauses for the other, but both need to know what the other is doing.

Yes, in two distinct ways. First, if you are on rifampicin, it can reduce blood levels of some checkpoint inhibitor drugs, potentially making them less effective. Second, immunotherapy activates the immune system, which can trigger inflammation at sites of old TB — even when the infection has been treated — in a reaction sometimes called immune reconstitution. NCCN guidance recommends TB screening before starting immunotherapy, particularly in settings like India where TB is common. Tell your oncologist your full TB history before checkpoint inhibitor treatment begins.

Latent TB means TB bacteria are present in your body in a dormant state — you have no symptoms and are not infectious. In a healthy immune system, latent TB usually stays dormant. Cancer treatment changes this. Chemotherapy, steroids, and immunotherapy can all suppress or alter the immune response that keeps dormant bacteria from becoming active. NCCN guidelines recommend screening for latent TB before starting immunotherapy in people from high-burden countries. If latent TB is found, preventive TB treatment may be started before immunosuppressive cancer treatment begins.

Yes. Cancer itself, and especially immunosuppressive cancer treatment, can allow dormant bacteria to reactivate — even years after a complete course of TB treatment. This is not a reason to avoid cancer treatment; it is a reason to tell your oncologist about your TB history so they can screen appropriately and plan accordingly. In high-burden settings, TB reactivation during cancer treatment is a recognised risk that your team is trained to watch for.

Liver function tests are the most important to have regularly, because both TB medicines and many cancer treatments affect the liver, and the combined load can be substantial. How often these tests are done depends on your specific combination of medicines. Your team will set the monitoring schedule. Do not skip liver function tests even if you feel well — liver strain from combined treatments can be present before you notice any symptoms, and catching it early keeps your options open.

Yes. Tell your oncologist even if your TB was treated and fully cleared years or decades ago. Past TB can leave areas of scarring that may appear on imaging and be misread as cancer spread. Latent infection may also persist, and immunosuppression from cancer treatment can reactivate it. Knowing your history allows your team to interpret scans correctly, decide whether latent TB screening is needed, and plan your treatment with the full picture.

Yes. Drug-resistant TB — whether MDR-TB or XDR-TB — requires longer, more complex regimens that include medicines with their own liver, nerve, and heart-related side effects. Some of these overlap with cancer treatment side effects and can compound them. Tell your oncologist about any drug-resistant TB at the first appointment. Your oncology team and the MDR-TB programme need to plan together so that both regimens can be given safely alongside each other.